Loomba R, Morgan E, Watts L et al (2020) Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Over the past decades, several randomized clinical trials (RCTs) have shown that GLP-1 RAs improve cardiovascular outcomes in patients with type 2 DM (T2DM) who have established CVDs or are at risk, as well as in individuals with CKD [16,17,18,19]
With melanoma of the lip, slightly more males are at risk
GLP-1 medications are quickly generating a new category of consumers, who want not just healthier, but nutrient-dense foods that are high in protein and fiber, low in sugar and carbohydrates